High expression of CLDN6 is associated with worse overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC), especially in different clinical subgroups of UCEC, which were analyzed by integrative multiple omics in pan-cancer [48]. The gene discussed is CLDN6; the disease is cancer.